دورية أكاديمية
Is HCV elimination among persons living with HIV feasible? Data from the NoCo study in the setting of the ICONA cohort.
| العنوان: | Is HCV elimination among persons living with HIV feasible? Data from the NoCo study in the setting of the ICONA cohort. |
|---|---|
| المؤلفون: | d'Arminio Monforte A; Icona Foundation, Milan, Italy., Tavelli A; Icona Foundation, Milan, Italy., Rossotti R; Infectious Diseases Unit, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy., Gagliardini R; Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy., Saracino A; Clinic of Infectious Diseases, Department of Biomedical Sciences and Human Oncology, University of Bari, University Hospital Policlinico, Bari, Italy., Lo Caputo S; Department of Clinical and Surgical Sciences, University of Foggia, Foggia, Italy., Sala M; Unit of Infectious and Tropical Diseases, ASST Santi Paolo e Carlo, University of Milan, Milan, Italy., Quiros-Roldan E; Department of Clinical and Experimental Sciences, Unit of Infectious and Tropical Diseases, University of Brescia, ASST Spedali Civili di Brescia, Brescia, Italy., Mussini C; AOU of Modena, Clinic of Infectious Diseases, University of Modena and Reggio Emilia, Modena, Italy., Girardi E; Scientific Direction, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy., Cozzi-Lepri A; Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, UCL, London, UK., Antinori A; Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy., Puoti M; Infectious Diseases Unit, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.; University of Milano-Bicocca, Milan, Italy. |
| مؤلفون مشاركون: | NoCo Study of the Icona cohort |
| المصدر: | Liver international : official journal of the International Association for the Study of the Liver [Liver Int] 2023 Oct; Vol. 43 (10), pp. 2130-2141. Date of Electronic Publication: 2023 Aug 31. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 101160857 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1478-3231 (Electronic) Linking ISSN: 14783223 NLM ISO Abbreviation: Liver Int Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Malden, MA : Wiley-Blackwell Original Publication: Oxford, UK : Blackwell Munksgaard, c2003- |
| مواضيع طبية MeSH: | COVID-19* , Hepatitis C*/diagnosis , Hepatitis C*/drug therapy , Hepatitis C*/epidemiology , HIV Infections*/drug therapy , HIV Infections*/epidemiology, Humans ; Child ; Antiviral Agents/therapeutic use ; Prospective Studies ; Reinfection ; RNA ; Viremia |
| مستخلص: | Background and Aims: Whether the HCV test-and-treat strategy impacted on the rate of new HCV infections among PLWH in Italy is unknown. Methods: Prospective study of PLWH in the ICONA network. At baseline, PLWH were tested for HCV-Ab; HCV-RNA (if HCV-Ab positive) and, if positive, treated with DAA. SVR12 indicated eradication. Seroconversions and re-infections were evaluated yearly in HCV-Ab neg and HCV-RNA neg at first screening. We estimated the following: HCV seroconversions, incidence of HCV reinfections, and access to DAA and SVR12 rates tighter with factors associated with each outcome. Data were analysed by Cox regression, Poisson regression and logistic regression models. Results: Sixteen thousand seven hundred and forty-three PLWH were included; 27.3% HCV-Ab positive; of these, 39.3% HCV-RNA positive. HCV seroconversion incidence: .48/100 PYFU (95% CI: .36-.65); re-infections incidence: 1.40/100 PYFU (95% CI: .91-2.04). The risk factor for HCV re-infection was young age: aIRR 1.85, 95% CI: 1.17-2.95) per 10 years younger. 86.4% of HCV viremic in follow-up started DAA. PWID vs. heterosexuals (aHR .75, 95% CI .62-.90), HIV-RNA >50 copies/mL (aHR .70, 95% CI .56-.87), HCV genotype other than G1, G2, G3, G4 or with multiple/missing HCV genotype and post-COVID-19 calendar periods were associated with lower DAA access. 922/965 (95.5%) PLWH achieved SVR12. We estimated 72% reduction of chance to achieve SVR12 in PLWH with a CD4 count <200/mm 3 (vs. CD4 ≥200/mm 3 aOR .18, 95% CI: .07-.46). 95.5% of DAA-treated individuals eradicated HCV, but they represent only 53.2% of HCV viremic PLWH and 66.4% of those in follow-up. HCV-RNA positivity by year decreased from 41.7% in 2017 to 11.7% in 2022. Conclusions: The screening-and-treat campaign implemented in Italy, even if only partially effective, resulted in a dramatic drop in HCV circulation in our cohort. (© 2023 The Authors. Liver International published by John Wiley & Sons Ltd.) |
| References: | Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology. 2008;48(2):418-431. doi:10.1002/HEP.22375. Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol. 2014;61(1 Suppl):S58-S68. doi:10.1016/J.JHEP.2014.07.012. de Martel C, Maucort-Boulch D, Plummer M, Franceschi S. World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma. Hepatology. 2015;62(4):1190-1200. doi:10.1002/HEP.27969. Petruzziello A. Epidemiology of hepatitis B virus (HBV) and hepatitis C virus (HCV) related hepatocellular carcinoma. Open Virol J. 2018;12(1):26-32. doi:10.2174/1874357901812010026. Asselah T, Kowdley KV, Zadeikis N, et al. Efficacy of glecaprevir/pibrentasvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2, 4, 5, or 6 infection without cirrhosis. Clin Gastroenterol Hepatol. 2018;16(3):417-426. doi:10.1016/j.cgh.2017.09.027. Feld JJ, Jacobson IM, Hézode C, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373(27):2599-2607. doi:10.1056/NEJMOA1512610. Gane EJ, Stedman CA, Hyland RH, et al. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. Gastroenterology. 2014;146:736-743.e1. doi:10.1053/j.gastro.2013.11.007. Bourlière M, Gordon SC, Flamm SL, et al. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. N Engl J Med. 2017;376(22):2134-2146. doi:10.1056/NEJMOA1613512. Kusejko K, Salazar-Vizcaya L, Shah C, et al. Sustained effect on hepatitis C elimination among men who have sex with men in the Swiss HIV Cohort Study: a systematic re-screening for hepatitis C RNA two years following a nation-wide elimination program. Clin Infect Dis. 2022;75:1723-1731. World Health Organization. Guidelines for the screening, care and treatment of persons with chronic hepatitis C infection. Updated version. 2016. Fengyi J, Jin F, Dore GJ, et al. Prevalence and incidence of hepatitis C virus infection in men who have sex with men: a systematic review and meta-analysis. Articles Lancet Gastroenterol Hepatol. 2021;6:39-56. doi:10.1016/S2468-1253(20)30303-4. Lazarus JV, Wiktor S, Colombo M, Thursz M. EASL international liver foundation. Micro-elimination-a path to global elimination of hepatitis C. J Hepatol. 2017;67:665-666. European Centre for Disease Prevention and Control. Hepatitis C. ECDC. Annual Epidemiological Report for 2020. ECDC; 2022. The Polaris Observatory HCV Collaborators. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Lancet Gastroenterol Hepatol. 2022;7:396-415. Agenzia Italiana del Farmaco; AIFA. https://www.aifa.gov.it/aggiornamento-epatite-c. 2017. Falade-Nwulia O, Sulkowski MS, Merkow A, Latkin C, Mehta SH. Understanding and addressing hepatitis C reinfection in the oral direct-acting antiviral era. J Viral Hepat. 2018;25(3):220-227. doi:10.1111/jvh.12859 PMID: 29316030; PMCID: PMC5841922. Stasi C, Silvestri C, Voller F. Update on hepatitis C epidemiology: unaware and untreated infected population could be the key to elimination. SN Compr Clin Med. 2020;2(12):2808-2815. doi:10.1007/S42399-020-00588-3. Blach S, Kondili LA, Aghemo A, et al. Impact of COVID-19 on global HCV elimination efforts. J Hepatol. 2021;74(1):31-36. doi:10.1016/j.jhep.2020.07.042 Epub 2020 Aug 7. PMID: 32777322; PMCID: PMC7411379. Rossetti B, Bai F, Tavelli A, et al. Evolution of the prevalence of HCV infection and HCV genotype distribution in HIV-infected patients in Italy between 1997 and 2015. Clin Microbiol Infect. 2017;24:422-427. pii: S1198-743X(17)30405-6. doi:10.1016/j.cmi.2017.07.021. Chou R, Wasson N. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection. Ann Intern Med. 2013;158(11):807. doi:10.7326/0003-4819-158-11-201306040-00005. Pawlotsky JM, Negro F, Aghemo A, et al. European Association for the Study of the Liver: Recommendations on treatment of hepatitis C: final update of the series. J Hepatol. 2020;73(5):1170-1218. doi:10.1016/j.jhep.2020.08.018.Epub. Platt L, Easterbrook P, Gower E, et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect Dis. 2016;16(7):797-808. doi:10.1016/S1473-3099(15)00485-5. Houghton M. The long and winding road leading to the identification of the hepatitis C virus. J Hepatol. 2009;51(5):939-948. doi:10.1016/j.jhep.2009.08.004. d'Arminio Monforte M, De Luca Puoti A, ICONA Foundation study group. Evolution of the prevalence of HCV infection and HCV genotype distribution in HIV-infected patients in Italy between 1997 and 2015. Clin Microbiol Infect. 2017;24:422-427. pii: S1198-743X(17)30405-6. doi:10.1016/j.cmi.2017.07.021. Puoti M, Lorenzini P, Cozzi-Lepri A, et al. Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus. Clin Microbiol Infect. 2017;23:267.e1-e267.e4. Boesecke C, Grint D, Soriano V, et al. Hepatitis C seroconversions in HIV infection across Europe: which regions and patient groups are affected? Liver Int. 2015;35(11):2384-2391. doi:10.1111/LIV.12848. Trouiller P, Velter A, Saboni L, et al. Injecting drug use during sex (known as “slamming”) among men who have sex with men: results from a time-location sampling survey conducted in five cities, France. Int J Drug Policy. 2020;79:102703. Wan Z, Sun P, Dzakah EE, Huang L, Shuai P, Liu Y. Reinfection rate of hepatitis C in HIV-positive men who have sex with men: a systematic review and meta-analysis. Frontiers (Boulder). 2022;10:855989. https://www.crd. Hosseini-Hooshyar S, Hajarizadeh B, Bajis S, et al. Risk of hepatitis C reinfection following successful therapy among people living with HIV: a global systematic review, meta-analysis, and meta-regression. Lancet HIV. 2022;9(6):e414-e427. doi:10.1016/S2352-3018(22)00077-7. Quaranta MG, Ferrigno L, Monti M, et al. Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort. Hepatol Int. 2020;14(3):362-372. doi:10.1007/S12072-020-10034-0. |
| فهرسة مساهمة: | Investigator: A Costantini; A Saracino; E Milano; F Maggiolo; C Suardi; E Quiros Roldan; C Minardi; B Menzaghi; C Abeli; L Chessa; F Pes; BM Celesia; D Scuderi; A Pan; P Brambilla; G Mazzarello; LA Nicolini; M Lichtner; A Carraro; A Chiodera; P Milini; G Nunnari; G Pellicanò; M Puoti; C Uberti Foppa; A De Bona; S Antinori; C Moioli; G Morsica; L Gazzola; A Giacomelli; I Gentile; F Borrelli; C Lazzaretti; R Corsini; A Antinori; E Grilli; L Sarmati; E Teti; R Cauda; S La Monica; A Cascio; M Trizzino; D Francisci; E Schiaroli; G Madeddu; A De Vito; M Fabbiani; B Rossetti; MB Pasticci; C Di Giuli; G Starnini; A Ialungo; A d'Arminio Monforte; A Antinori; S Antinori; A Castagna; R Cauda; G Di Perri; E Girardi; R Iardino; A Lazzarin; GC Marchetti; C Mussini; E Quiros-Roldan; L Sarmati; B Suligoi; F von Schloesser; P Viale; A d'Arminio Monforte; A Antinori; A Castagna; F Ceccherini-Silberstein; A Cingolani; A Cozzi-Lepri; E Girardi; A Gori; S Lo Caputo; G Marchetti; F Maggiolo; C Mussini; M Puoti; CF Perno; C Agrati; A Antinori; F Bai; A Bandera; S Bonora; A Calcagno; D Canetti; A Castagna; F Ceccherini-Silberstein; A Cervo; S Cicalini; A Cingolani; P Cinque; A Cozzi-Lepri; A d'Arminio Monforte; A Di Biagio; R Gagliardini; A Giacomelli; E Girardi; N Gianotti; A Gori; G Guaraldi; S Lanini; G Lapadula; M Lichtner; A Lai; S Lo Caputo; G Madeddu; F Maggiolo; V Malagnino; G Marchetti; C Mussini; S Nozza; CF Perno; S Piconi; C Pinnetti; M Puoti; E Quiros Roldan; R Rossotti; S Rusconi; MM Santoro; A Saracino; L Sarmati; V Spagnuolo; N Squillace; V Svicher; L Taramasso; A Vergori; F Bovis; A Cozzi-Lepri; I Fanti; A Rodano'; M Ponzano; A Tavelli; A Bove; M Cernuschi; L Cosmaro; M Errico; A Perziano; V Calvino; S Carrara; S Graziano; G Prota; S Truffa; D Vincenti; Y D'Errico; IA Giacometti; A Costantini; V Barocci; A Saracino; C Santoro; E Milano; F Maggiolo; C Suardi; P Viale; L Badia; S Cretella; EM Erne; A Pieri; E Quiros Roldan; E Focà; C Minardi; B Menzaghi; C Abeli; L Chessa; F Pes; P Maggi; L Alessio; B Cacopardo; B Celesia; J Vecchiet; A Pan; S Dal Zoppo; D Segala; F Vichi; D Pietro; T Santantonio; S Ferrara; M Bassetti; E Pontali; S Blanchi; N Bobbio; G Mazzarello; M Lichtner; L Fondaco; S Piconi; C Molteni; S Rusconi; G Canavesi; A Chiodera; P Milini; G Nunnari; G Pellicanò; G Marchetti; S Antinori; A Lazzarin; G Rizzardini; M Puoti; A Gori; A Castagna; A Bandera; V Bono; MV Cossu; A Giacomelli; R Lolatto; MC Moioli; L Pezzati; C Tincati; C Mussini; C Puzzolante; P Bonfanti; G Lapadula; V Sangiovanni; I Gentile; V Esposito; N Coppola; FM Fusco; G Di Filippo; V Rizzo; N Sangiovanni; S Martini; AM Cattelan; S Marinello; A Cascio; C Colomba; D Francisci; E Schiaroli; G Parruti; F Sozio; P Blanc; A Vivarelli; C Lazzaretti; R Corsini; M Andreoni; A Antinori; R Cauda; C Mastroianni; A Cingolani; V Mazzotta; S Lamonica; M Capozzi; A Mondi; M Rivano Capparuccia; G Iaiani; C Stingone; L Gianserra; J Paulicelli; MM Plazzi; G d'Ettore; M Fusto; M Cecchetto; F Viviani; G Madeddu; A De Vito; M Fabbiani; F Montagnani; A Franco; R Fontana Del Vecchio; BM Pasticci; C Di Giuli; GC Orofino; G Calleri; G Di Perri; S Bonora; G Accardo; C Tascini; A Londero; V Manfrin; G Battagin; G Starnini; D Farinacci Keywords: HCV; PLWH; eradication; reinfections; seroconversions |
| المشرفين على المادة: | 0 (Antiviral Agents) 63231-63-0 (RNA) |
| تواريخ الأحداث: | Date Created: 20230831 Date Completed: 20230919 Latest Revision: 20230928 |
| رمز التحديث: | 20231215 |
| DOI: | 10.1111/liv.15700 |
| PMID: | 37649460 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1478-3231 |
|---|---|
| DOI: | 10.1111/liv.15700 |